Five commercial assays were compared to a standardized complement fixation (CF) test for the detection of antibody to cytomegalovirus. Two hundred and thirty serum specimens were analyzed. In addition, nine pairs of acute-and convalescent-phase sera were tested by two of the commercial assays. The assays were compared as to sensitivity, specificity, and positive and negative predictive value, as well as incidence of false-positive and -negative results. Primary infections occur in serologically negative individuals after exposure to the virus. Secondary infections are a result of activation of latent infections or reinfection of a serologically positive individual (7).
Cytomegalovirus (CMV) infections can be asymptomatic or have a variety of clinical symptoms, with patients presenting with an infectious mononucleosis syndrome or hepatitis, which vary depending on several factors. Concurrent infections, drug therapy, age, and immune status all play a major role in the severity of infections due to CMV. Persons at risk for acquired immunodeficiency syndrome have increased prevalence of CMV infection, but its role in the syndrome and especially Kaposi's sarcoma remains unclear.
Primary infections occur in serologically negative individuals after exposure to the virus. Secondary infections are a result of activation of latent infections or reinfection of a serologically positive individual (7) .
CMV is a leading cause of congenital viral infections and is associated with infections after blood transfusions, renal transplants, and bone marrow transplants (2, 14, 15, 17) . The CMV antibody status of the transfusion or transplant donor and recipient is an important factor in the management of patients at risk, such as low-birth-weight neonates and transplant recipients (1, 11, 13, 15, 19) .
Although the presence of antibody to CMV does not indicate infectious blood or tissues, it is a marker indicating previous infection. Serologic tests for the detection and quantitation of antibodies to CMV are a valuable aid in determining clinical diagnosis (18) . The presence of specific CMV antibody as evidence of past or present infection is the most valuable indirect indicator of CMV infection or a potentially infective donor. Demonstration of a significant rise in antibody titer from the acute to the convalescent phase substantiates acute infection with CMV.
Recently, several studies report results of comparisons between several serological assays for the detection of CMV antibody (3-5, 8, 9, 16 We compared five commercial assays with the standardized complement fixation (CF) assay by using samples from clinical patients and organ or bone marrow donors and recipients. In addition, two of the assays were used to detect seroconversion in nine pairs of sera previously tested for seroconversion by an anticomplement immunofluorescence assay (ACIF).
MATERIALS AND METHODS
Serum specimens. Sera were (i) 200 samples sent to the clinical laboratory and (ii) 30 samples from patients with acquired immunodeficiency syndrome from the University of California at San Francisco, (iii) 9 pairs of acute-and convalescent-phase samples from Mt. Zion Hospital, San Francisco (L. Drew). All samples were stored in capped glass tubes at -20°C.
CF. Serum samples were submitted to the microbiology laboratory of the San Francisco Department of Public Health for CMV antibody testing by the standard CF microtiter method previously described (10) . Briefly, the sera were diluted in veronal-buffered saline, heat inactivated, and further diluted on microtiter plates in serial twofold dilutions. The screening dilution used was 1:8. degree of hemolysis in the supernatant fluid was read visually. The CMV antibody titer was the highest serum dilution demonstrating no more than 25% hemolysis (.75% CF). AUl appropriate controls were included in each run.
ACIF. The nuclear ACIF was used as the standard method for determining acute CMV infection with paired samples.
Samples were submitted to and tested at Mt. Zion Hospital and Medical Center, San Francisco, Calif. The ACIF procedure uses isolated nuclei from CMV-infected human fibroblasts as described previously (12) . Briefly, isolated nuclei were fixed on glass slides in acetone at room temperature for 10 min. Heat-inactivated serum (560C for 30 min) was added to slides and incubated at 37°C for 60 min under a moist cover. Slides were washed for 5 min in phosphate-buffered saline. Guinea pig complement (M. A. Bioproducts) was added and incubated at 37°C for 30 min undér a moist cover. Slides were washed as described above. Fluorescein isothiocyanate-conjùgated goat anti-guinea pig complement C3 (B1C-BA) (Cappel Laboratories, Cochranville, Pa.) was added and incubated at 37°C for 30 min under a moist cover. Slides were washed as described above and ait dried. Fluorescence was examined without cover slips under a Zeiss epifluorescence microscope. Nuclear fluorescence was graded as 0, ±, 1+, 2+, or 3+. Antibody titer was determined as the highest serum dilution producing 1+ specific nuclear fluorescence. Uninfected control nuclei were included in each run as were positive and negative control sera.
EIA. Three enzyme immunoassays (EIA) were evaluated. The CMV Total AB EIA (Abbott Laboratories, North Chicago, Ill.) uses a 1:21 dilution of serum. Serum was incubated with the solid-phase bead coated with CMV antigen (AD 169) for 60 min at 40C. Beads were washed three times with deionized water with the Pentawash II (Abbott). Horseradish peroxidase-conjugated goat anti-human immunoglobulin (Ig) was added to each bead and incubated for 30 min at 40°C. Beads were again washed and transferred to plastic tubes (12 by 75 mm). O-Phenylenediamine substrate was added to each tube and incubated for 30 min at 22°C. Sulfuric acid (1 N) was added to each tube. Absorbance was read on a Quantum Il photometer (Abbott). A cutoff value of the mean absorbance of negative controls plus 0.075 was calculated. Samples with absorbance greater than 10% above the cutoff were positive. Samples less than 10% of the cutoff were negative. Samples within 10% of the cutoff value were equivocal and were retested.
The CMV RQ Bio-Enzabead (Litton Bionetics, Kensington, Md.) uses a 1:50 dilution of serum. All reagents were prewarmed at 37°C. Serum was incubated with two solid-phase, plastic-coated ferrous beads, one coated with CMV antigen (AD 169) and the second coated without CMV, for 10 min at 37°C. Beads were washed 12 times in water-0.05% Tween 20 with a magnetic transfer device.
Beads were transferred to a plate containing peroxidaseconjugated goat anti-human IgG (heavy and light chain specific) and incubated for 10 min at 37°C. Beads were washed as before and transferred to a plate containing 0.03% 2,2'-azino-di(3-ethyl)benzthiazoline sulfonate and incubated for 10 min at 37°C. Sodium fluoride (1.25%) was added to each well and mixed. Absorbance was read at 690 nm on an LBI-300 enzyme-linked immunosorbent assay (ELISA) reader (Litton). A calibration curve was drawn with absorbance versus ELISA values provided by the manufacturer for six calibrators. Absorbances of samples from patients were converted to ELISA values from the calibration curve. An ELISA value <0.085 from the antigen bead was considered negative. The ELISA value from the antigen and control beads was used to calculate a delta value and a ratio. The ELISA value of the antigen bead minus the control bead equals delta. The ELISA value of the antigen bead divided by that of the control bead equals the ratio. A delta value of -0.025 and a ratio of -0.028 were considered positive. A delta value of 0.021 to 0.024 and a ratio of 0.023 to 0.027 were equivocal and were retested. Delta <0.021 and ratio <0.023 were negative.
The Cytomegelisa test (M. A. Bioproducts) used a 1:26 dilution of serum. Serum was placed into 2 wells of a 96-well tray and incubated for 45 min at 22°C in a humidified chamber. One well was coated with CMV antigen (AD 169), and the second well was coated with a suspension without CMV. Sera were decanted, and the plate was washed with phosphate-buffered saline-0.05% Tween 20 for 3 min. Washing was repeated twice after the initial wash. Excess buffer was removed by blotting. Alkaline phosphatase-conjugated rabbit anti-human IgG (heavy and light chain specific) was added to each well and incubated for 45 min at 22°C in a humidified chamber. Conjugate was decanted and the plate was washed as described above. p-Nitrophenyl phosphate substrate was added to each well and incubated for 45 min at 22°C. NaOH (1 N) was added to each well and mixed. The plates were read at 405 nm on a Titertek Multiskan (Flow Laboratories). The absorbance from the control antigen well was subtracted from that of the CMV antigen well. Three calibrators supplied were used to construct a calibration curve by linear regression. The regression used calibrator absorbance values versus Cytomegelisa values provided by the manufacturer. A correlation coefficient .0.95 is necessary for an acceptable test. Two control sera need to be within manufacturer-defined limits for an acceptable test. Absorbance was converted to Cytomegelisa values with the calibration curve. Values s0.22 were negative, those between 0.23 and 0.24 were equivocal, and those .0.25 were positive. Equivocal samples were retested.
IFA. An indirect fluorescent-antibody test (IFA) was used on selected samples. The CMV antibody IFA (ElectroNucleonics, Inc., Columbia, Md.) uses a 1:8 dilution for IgM. For IgG, a 1:16 dilution of serum was placed in a well containing a mixture of uninfected and CMV-infected human foreskin fibroblasts and incubated for 30 min at 22°C under a moist cover. For IgM, the first incubation was 60 min at 22°C under a moist cover. Slides were washed with three 5-min washes in phosphate-buffered saline. Slides were air dried. Fluorescein isothiocyanate-conjugated goat anti-human IgG (heavy and light chain specific) or fluorescein isothiocyanate-conjugated goat anti-human IgM (heavy chain specific) was added to each well and incubated for 30 min at 22°C under a moist cover. Slides were washed as described above and air dried. Cover slips were placed on slides with buffered glycerol filling the interface. Fluorescence was read on a Zeiss epifluorescence microscope. Fluorescent intranuclear inclusions in infected cells were considered positive.
IHA. An indirect hemagglutination assay (IHA) was evaluated. The CMV IHA (Cetus Corp., Emeryville, Calif.) uses a 1:4 dilution of serum. Samples were pipetted into 2 wells each of a 96-well V-bottom plate. One well contained CMV antigen (AD 169)-coated human O-erythrocytes. A second well contained noncoated erythrocytes. The plates were covered with plate sealers, and the reactants were mixed. The plates were incubated at 22°C on a moist towel. Cell patterns were read on a plate viewer with a concave magnifying mirror at 90 min, 4 h, and 18 h. Patterns were interpreted in relation to negative and low and high positive of the other assays were retested by CF at a dilution of 1:4. The IFA was run on any sample which did not agree in all the assays. IFA was used as the confirmatory test, since IgM-specific testing was desired. Percent sensitivity, specificity, positive and negative predictive value, and the incidence of false-positive and -negative results were calculated as described in Fig. 1 , which was adapted from Griner et al. (6) . Table 1 lists the results as total number positive or negative compared with CF. Of the 230 sera tested, all were used in the comparison with the CF test. Forty-five percent (103 of 228) of the sera were positive by CF, and two samples (0.9%) were inconclusive by CF. One of these samples showed a nonspecific hemolysis reaction to control antigen in the CF and was negative in all the other assays. The second was anticomplementary and positive in the other assays. All of the assays had some discrepant results when compared with CF for discriminating positive versus negative results. Table 2 summarizes the performance characteristics of all of the assays. Percent sensitivity, specificity, false-positive and -negative rates, and positive and negative predictive values are shown. These resuIts were calculated as de- '-, Negative when tested on unuiluteu serum.
RESULTS
incidence of false-negative results was higher with EIA than with IHA or LA. The Abbott EIA is not designed for detection of acute infection with acute-and convalescent-phase serum pairs. This eliminates the use of this assay in a laboratory setting in which serological verification of acute CMV is needed. The Abbott EIA also detected only 10 samples as positive out of the 32 discrepant samples. The Litton EIA is designed to detect acute infection with paired sera. Since the lowest number of positive sera were detected by the Litton EIA and the lowest number of discrepant samples were detected as positive, paired sera were not tested by this method. The M. A. Bioproducts EIA is designed to detect acute infection with paired sera. However, paired serum sarnples were not tested with the M. A. Bioproducts EIA, since fewer positive sera were detected among the discrepant samples than were detected with IHA or LA.
Some of the discrepancies in discriminating positive versus negative results among all the assays may be attributed to the screening dilution used. Although we did repeat negative CF samples at lower than 1:8 dilutions, we did not retest negative specimens with any of the commercial assays at dilutions less than those recommended by the manufacturer. If one ignores differences in sensitivity due to the methodology and only considers the screening dilution, the commercial assays can be ranked in the following order based on number of specimens detected as positive and the screening dilution. The highest number of positive sera was detected by the LA test, which uses undiluted serum. The IHA, using a 1:4 dilution of serum, detected the next highest number of positive sera. The M. A. Bioproducts EIA, which uses a 1:26 dilution, was next. The Abbott EIA, at a 1:21
